GENESIS THERAPEUTICS
Their academia-leading research was the initial component of our expanding portfolio of AI technologies. They are combining novel deep neural networks, biophysical simulation, and massively scalable computing infrastructure to achieve industry-leading performance in a molecular generation and property prediction. The company was founded in 2019 and based in South San Francisco, California.
GENESIS THERAPEUTICS
Industry:
Artificial Intelligence Biotechnology Information Technology
Founded:
2019-11-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.genesistherapeutics.ai
Total Employee:
11+
Status:
Active
Total Funding:
56.1 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Google Universal Analytics
Similar Organizations
Dyno Therapeutics
Dyno Therapeutics is a biotechnology company that uses artificial intelligence for gene therapy.
Emedgene
Emedgene provides data-driven AI solutions for genomic diagnostics and discovery at scale.
Raze Therapeutics
Raze Therapeutics, Inc., a biotechnology company, engages in the discovery and development of oncology therapeutics.
Current Advisors List
Board_member
2020-01-01
Board_observer
2020-01-01
Board_observer
Current Employees Featured
Evan Feinberg CEO and Founder @ Genesis Therapeutics
CEO and Founder
2019-01-01
Ben Sklaroff Co-Founder and VP Engineering @ Genesis Therapeutics
Co-Founder and VP Engineering
Founder
Investors List
T. Rowe Price
T. Rowe Price investment in Series A - Genesis Therapeutics
Jazz Venture Partners
Jazz Venture Partners investment in Series A - Genesis Therapeutics
Menlo Ventures
Menlo Ventures investment in Series A - Genesis Therapeutics
Radical Ventures
Radical Ventures investment in Series A - Genesis Therapeutics
Propagator Ventures
Propagator Ventures investment in Series A - Genesis Therapeutics
Jeffrey Rothschild
Jeffrey Rothschild investment in Series A - Genesis Therapeutics
Rock Springs Capital
Rock Springs Capital investment in Series A - Genesis Therapeutics
Ulu Ventures
Ulu Ventures investment in Series A - Genesis Therapeutics
Open Field Capital
Open Field Capital investment in Series A - Genesis Therapeutics
Felicis Ventures
Felicis Ventures investment in Series A - Genesis Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-04-28 | Genesis Therapeutics Expands Executive Team with Addition of Will McCarthy as Chief Business … |
Official Site Inspections
http://www.genesistherapeutics.ai Semrush global rank: 5.72 M Semrush visits lastest month: 1.46 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Genesis Therapeutics"
Genesis Therapeutic - Crunchbase Company Profile
Contact Email info@genesistherapeutics.ai Phone Number +1(208) 991-4716 Genesis Therapeutics is a company that has its roots in academic research, …See details»
People - Genesis Therapeutics
Nov 21, 2019 Genesis integrates biotech veterans with leading AI researchers, all driven to optimize drug discovery and create life-changing medicines. We are supported by world-leading investors who share this long-term vision. Genesis …See details»
Genesis Therapeutics - LinkedIn
Genesis Therapeutics | 14,992 followers on LinkedIn. Unifying AI and Biotech to accelerate the discovery of new medicines | Genesis Therapeutics – headquartered in Burlingame, CA, with a fully ...See details»
Genesis Research - Research | Genesis Therapeutics
Genesis Research is pioneering the field of Molecular AI Basic research is the foundation of Genesis Therapeutics, a company that emerged from pioneering Ph.D. research by founder & …See details»
Gilead and Genesis Therapeutics Announce Strategic …
Sep 10, 2024 GEMS integrates proprietary AI methods, including language models, diffusion models and physical ML simulations, to generate and optimize molecules for complex targets. …See details»
Incyte and Genesis Therapeutics Announce Strategic AI-focused …
Feb 20, 2025 Genesis Therapeutics, Inc. is an AI-focused biotechnology company leveraging its generative and predictive AI platform, GEMS (Genesis Exploration of Molecular Space), for …See details»
Genesis Therapeutics Expands Leadership Team with …
Dec 11, 2024 For more information on Genesis, please visit the company’s website at www.genesistherapeutics.ai. Contacts. Investors: Will McCarthy Chief Operating Officer …See details»
Genesis Therapeutics 2025 Company Profile: Valuation, Funding ...
Genesis Therapeutics General Information Description. Developer of a computational platform designed for the discovery of small-molecule drugs. The company leverages a proprietary …See details»
Genesis Therapeutics - VentureRadar
Website: https://www.genesistherapeutics.ai. Develops AI-driven platforms for small molecule drug discovery, integrating generative and predictive methods to generate and optimize …See details»
Genesis Therapeutics - Company Profile - Tracxn
Feb 22, 2025 Genesis Therapeutics - Developer of computational platform for drug discovery using AI. Raised a total funding of $300M over 5 rounds from 17 investors. Founded by Evan …See details»
Genesis Therapeutics Announces New Equity Investment and …
Nov 13, 2024 Genesis Therapeutics is an AI-focused biotechnology company leveraging its generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space) …See details»
Genesis Therapeutics raises $52M A round for its AI ... - TechCrunch
Dec 2, 2020 The resulting representation is richer and more complex, a more complete picture of a molecule than you’d get from its chemical formula or a stick diagram showing the different …See details»
Genesis raises $200m for AI drug discovery engine - pharmaphorum
5 days ago It follows a string of other financings for companies applying AI to drug discovery in recent months, including a $95 million Series D for BenchSci, a €30 million round for French …See details»
Genesis Therapeutics Expands Leadership Team with …
Dec 11, 2024 BURLINGAME, Calif.--(BUSINESS WIRE)-- Genesis Therapeutics, a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for …See details»
Genesis Therapeutics Company Overview, Contact Details
Aug 21, 2023 AI-driven Drug Discovery Genesis Therapeutics leverages AI technology through its GEMS platform to accelerate small molecule drug discovery, presenting an opportunity for …See details»
AI Platform - Genesis Therapeutics
Jul 22, 2024 Genesis has pioneered state-of-the-art AI methods to predict protein-ligand structures, using diffusion models to efficiently sample the critical 3D structures for protein …See details»
AI drug designer Genesis Therapeutics forges $200M round with …
Aug 21, 2023 Genesis Therapeutics has forged a $200 million venture capital round to help turn its artificial intelligence-powered pipeline toward human testing. | First spun out of Stanford …See details»
Genesis Therapeutics Announces New Equity Investment and
Nov 13, 2024 BURLINGAME, Calif.--(BUSINESS WIRE)--Genesis Therapeutics, a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for …See details»
Global GenAI study reveals optimism and opportunities for health …
2 days ago Generative AI is at the forefront of global innovation in both health care and life sciences. To better understand how technology is being used, data and AI leader SAS and …See details»
Fierce Medtech Names Genesis Therapeutics a “Fierce 15” …
Mar 6, 2024 Investors: Will McCarthy Chief Operating Officer will@genesistherapeutics.ai Media: Azeem Zeekrya HDMZ genesis.pr@hdmz.com (312) 506-5244 More News From Genesis …See details»